DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Half Year Report

For the six months ended 30 June 2023

Doctor Care Anywhere Group PLC

Company number: 08915336

ARBN: 645 163 873

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Contents

Appendix 4D – Half Year Report	2
Directors' Report	6
Unaudited Interim Condensed Consolidated Financial Statements	11
Notes to the Interim Condensed Consolidated Financial Statements	16
Directors' Declaration	30
Independent Review Report to Doctor Care Anywhere Group PLC	31
Corporate Directory	33

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Appendix 4D – Half Year Report

Reporting Period

Current reporting period ("1H23"): 1 January 2023 to 30 June 2023

Previous corresponding period ("1H22"): 1 January 2022 to 30 June 2022

Basis of Preparation

This Appendix 4D has been prepared in accordance with measurement and recognition (but not disclosure) requirements of International Financial Reporting Standards in conformity with the requirements of the Companies Act 2006 (UK).

The interim results for the 6 months ended 30 June 2023 and the comparatives for 30 June 2022 are unaudited but have been reviewed by the Company's independent auditor. A copy of the review report is included at the end of this report.

Note all values in the Appendix 4D and Directors' Report are subject to rounding differences.

Results for Announcement to the Market

		1H23	1H22	Change	%
Revenue	£m's	19.2	15.2	4.0	*26.4%*
Net loss	£m's	(6.2)	(11.6)	5.5	*47.0%*
Net tangible assets per security	£'s	(0.00)	0.03	(0.03)	*(102.9%)*

Revenue

Revenue grew by 26.4% in 1H23 compared with 1H22, driven both by an increased volume of consultations delivered to the Company's growing base of Activated Lives and by an increase in the average price per consultation.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Net Loss

A summary of net loss adjusted for one-off charges is as follows:

		1H23	1H22	Change	%
Net loss	**£m's**	**(6.2)**	**(11.6)**	**5.5**	***47.0%***
Add back					
Restructuring costs	£m's	-	1.6		
GP2U impairment charge	£m's	1.7	-		
Underlying net loss	**£m's**	**(4.5)**	**(10.0)**	**5.6**	***55.5%***

Net loss for 1H23 includes an impairment charge of £1.7m against the carrying value of GP2U. Excluding this charge, underlying net loss for 1H23 was £4.5m.

Net loss for 1H22 includes one-off restructuring costs of £1.6 million. These costs represented redundancy and notice payments for employees departing the organisation. Adjusting for this, net underlying loss for 1H22 was £10.0 million.

Taking into account these adjustments, net underlying loss for 1H23 reduced by 56%, or £5.6m, compared with 1H22. This is through ongoing growth in the business and a focus on productivity improvements and margin expansion as the business drives towards profitability in 2024.

Net Tangible Assets Per Security

Net tangible assets decreased by £12.4 million from £12.1 million at 30 June 2022 to a net tangible liability of £0.3m million at 30 June 2023 (down 103%). This was driven by a combined net loss of £16.6m in 2H22 and 1H23 within which £4.2m related to impairment of intangible assets.

As a result of this, net tangible assets per security decreased from £0.03 at 1H22 end to £0.00 at 1H23 end.

Dividends

No dividends have been declared, nor were any paid in the prior period.

Joint Ventures

The Company is party to a joint venture with AXA PPP Healthcare Group Limited ("AXA Health"). The Company and AXA Health each hold 50% of the issued share capital of Doctor at Hand Diagnostics Limited.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Going Concern

These financial statements have been prepared on a going concern basis, which assumes that the Group and the Company will continue to be able to meet their liabilities as they fall due for the foreseeable future, which has been taken as 12 months from the date of approval of the Half Year Report.

The Directors have considered detailed cash flow forecasts to determine the appropriateness of preparing these financial statements on a going concern basis.

On 12 December 2022, the Company announced that it had entered into a four-year secured and guaranteed loan agreement with AXA Health to borrow up to £10.0m in 3 tranches ("Loan"). The Loan is to be used by the Company for general working capital purposes. At the date of this report, all three tranches have been drawn down. Under the terms and covenants of the loan, the Group is required to maintain a minimum cash balance; in August 2023 the Company agreed with AXA Health a reduction in the minimum from £3.0m to £1.5m in light of the Company's progress since December 2022. The minimum cash balance requirement will be subject to a further review in September 2024. Therefore, to prepare the accounts on a Going Concern basis, this minimum cash balance requirement must be met throughout the Going Concern period.

The forecast is dependent on a number of key assumptions and dependencies, the most material of which are as follows:

- Minimum growth of 30% in demand for consultations from the Company's patient base
- The ability to recruit and retain enough clinicians to meet patient demand
- The ability to drive productivity gains which underpin the Company's 2023 plan together with no material unanticipated increases in non-operating costs

Management has assessed all the above assumptions to be reasonable based on its expectations of the business going forward. As part of this going concern assessment, four scenarios were considered for the Group, being a management case and three other scenarios using a set of plausible downside assumptions to that management case. The management case is built up from detailed projections and the aforementioned assumptions. The downside scenarios considered were as follows:

- AXA Health consultations being 10% below the management case.
- The percentage of consultations treated by Advanced Nurse Practitioners ("ANPs") being 10ppt below the management case.
- The switch from a primarily locum based ANP staff base, to an employed ANP staff base taking four months longer than the management case.

In all three downside scenarios and for all three scenarios combined, the Group had adequate resources to continue in operational existence for the going concern period.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

In order for the Company to breach the terms of the AXA loan facility and therefore not to remain a Going Concern, the following combination of scenarios would be required:

- Consultation volumes to fall by 13.9% below the management case; and
- The percentage of consultations treated by ANPs being 10ppt below the management case; and
- The switch from a primarily locum based ANP staff base, to an employed ANP staff base taking four months longer than the management case.

Management considers the possibility of the above scenarios occurring concurrently to be low:

- July AXA volumes were largely in line with the management case, giving assurance over trading volumes.
- ANPs can treat a higher proportion of patient cases than included the management model.
- Management has a plan in place to increase the proportion of employed ANPs in its workforce.

In addition, the Directors consider that the Group is well positioned to manage its business risks and have had regard to a number of factors including current trading performance, the outcomes of comprehensive forecasting, and a range of possible future trading impacts. The Directors are of the view that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the next 12 months following the date of approval of the financial statements. For this reason, they continue to adopt a going concern basis in the preparation of these financial statements.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Directors' Report

The Directors present the condensed consolidated interim financial report of Doctor Care Anywhere Group PLC ("the Company" or "Doctor Care Anywhere") and its subsidiaries ("the Group") for the six months ended 30 June 2023 ("1H23").

Directors

The Directors in office during the reporting period and as at the date of this report are shown below:

- Romana Abdin — Independent Non-Executive Director
- David Ravech — Non-Executive Director
- John Stier — Independent Non-Executive Director, Independent Chairman from 28 March 2023
- Dr Aleksandra Spencer — Independent Non-Executive Director (appointed 3 July 2023)
- Richard Dammery — Independent Chairman (resigned 28 March 2023)
- Vanessa Wallace — Independent Non-Executive Director (resigned 28 March 2023)
- Simon Calver — Non-Executive Director (resigned 28 March 2023)

About Doctor Care Anywhere

Doctor Care Anywhere Group PLC is the UK's largest private provider of telehealth services. The Company works with insurers, healthcare providers and corporate customers to connect patients to a range of digitally-enabled telehealth services on its proprietary platform. It is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Operating and Financial Review

000's	1H23	1H22	Change	%	2H22	Change	%
Eligible Lives	2,837	2,526	311	*12.3%*	2,720	117	*4.3%*
Activated Lives	966	756	210	*27.8%*	869	97	*11.2%*
Consultations	377	303	74	*24.4%*	311	66	*21.2%*
Repeat Patients	265	206	59	*28.6%*	222	43	*19.4%*
First-Time Patients	111	97	14	*14.4%*	88	23	*26.1%*
Secondary-Care Journeys	20	14	6	*45.7%*	17	3	*20.0%*

Growth continued across all key operational metrics in 1H23. At the end of 1H23, Activated Lives were 966,000, up 28% on the prior comparative period ("pcp"). The Company added 97,000 Activated Lives in 1H23, slightly fewer than the 113,000 Activated Lives added in 2H22, primarily due to constraints in growing clinician capacity. The launch of Mixed Clinical Workforce ("MCW") in mid-June 2023 has significantly improved the Company's ability to source clinician capacity.

Consultation volumes grew to 377,000 in 1H23, up 24% on the pcp. Patient demand remains strong and continues to grow, as evidenced by the increases in both repeat patients and first-time patients, but consultation volume growth was also constrained by clinician capacity, with the Company experiencing very high utilisation of available consultations.

Following the launch of MCW in mid-June 2023, the Company expects clinician availability to improve. MCW refers to the addition of Advanced Nurse Practitioners ("ANPs") to the Company's clinical workforce. ANPs are educated to Masters level in clinical practice and have been assessed as competent in practice. They have the authority to make autonomous decisions in the assessment, diagnosis and treatment of patients.

MCW went live in mid-June and over 20,000 appointments were provided by ANPs in June and July, showing a strong uptake for the service. The launch of MCW has materially improved clinician supply with the Company already having around 80 ANPs to serve patients. MCW will also reduce DCA's cost to serve, key to driving margins and the Company becoming profitable in 2024.

The Company made progress with its secondary care proposition, which integrates primary and secondary care through the provision of GP consultations, diagnostic tests and review of such tests by specialist consultants. In 1H23, 20,000 patients completed this pathway, up 20% on 2H22. Growth and profitability in this area continues to underperform expectations, however, with work underway to improve this.

In addition to the above, in July 2023 the Company completed the sale of its Australian subsidiary GP2U to My Emergency Doctor (MED) for A$3.0m, of which A$0.5m was paid in cash, and the balance paid in shares in MED. The sale of GP2U enables the business to focus on its core UK market while reducing ongoing losses by £0.5m pa.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Finally, the Company has now fully drawn down on its £10.0m loan facility with AXA Health, following drawdown of tranche 3 of the loan in early July; and has agreed the reduction in minimum cash covenant described earlier. These steps, combined with ongoing growth, the efficiency gains achieved from the launch of MCW and the sale of GP2U, are expected to see the Company through to breakeven in Q1 2024.

Financial KPIs

Consolidated income statement

£m's	1H23	1H22	Change	%	2H22	Change	%
Revenue	**19.2**	**15.2**	**4.0**	***26.4%***	**14.2**	**5.0**	***35.3%***
Cost of sales	(10.8)	(8.8)	(2.0)	*(22.6%)*	(8.1)	(2.7)	*(32.7%)*
Gross Profit	**8.3**	**6.3**	**2.0**	***31.7%***	**6.0**	**2.3**	***38.8%***
Gross Profit Margin	*43.6%*	*41.8%*	*1.7 ppt*		*42.5%*	*1.1 ppt*	
Operating costs	(3.6)	(3.2)	(0.4)	*(13.1%)*	(3.2)	(0.4)	*(14.1%)*
Contribution	**4.7**	**3.1**	**1.6**	***50.8%***	**2.8**	**1.9**	***66.8%***
Contribution Margin	*24.6%*	*20.6%*	*4 ppt*		*19.9%*	*4.6 ppt*	
Non-operating costs	(8.3)	(13.9)	5.7	*40.6%*	(8.2)	(0.1)	*(1.1%)*
Share of JV profit/(loss)	0.0	0.2	(0.1)	*(82.9%)*	(0.3)	0.3	*109.9%*
EBITDA	**(3.5)**	**(10.7)**	**7.1**	***66.8%***	**(5.6)**	**2.1**	***37.2%***
EBITDA Margin	*(18.5%)*	*(63.1%)*	*44.7 ppt*		*(39.8%)*	*21.3 ppt*	
Depreciation and amortisation	(1.1)	(0.8)	(0.3)	*(38.2%)*	(1.1)	(0.1)	*(4.9%)*
EBIT	**(4.6)**	**(11.5)**	**6.8**	***59.5%***	**(6.7)**	**2.0**	***30.5%***
Finance income/(expense)	(0.2)	(0.0)	(0.2)	*n/m*	(0.0)	(0.2)	*(413.2%)*
Loss before tax	**(4.8)**	**(11.5)**	**6.6**	***57.8%***	**(6.7)**	**1.9**	***28.0%***
Tax	0.6	0.1	0.4	*395.6%*	0.1	0.4	*291.6%*
Loss after tax	**(4.3)**	**(11.4)**	**7.1**	***62.3%***	**(6.6)**	**2.3**	***35.0%***
Results from discontinued operations	(1.9)	(0.3)	(1.6)	*(601.1%)*	(2.8)	0.9	*33.0%*
Net loss	**(6.2)**	**(11.6)**	**5.5**	***47.1%***	**(9.4)**	**3.2**	***34.4%***
Net Operating Cash Flows	**(4.4)**	**(8.6)**	**4.2**	***48.6%***	**(6.0)**	**1.6**	***26.5%***

Commentary

Revenue in 1H23 was £19.2 million, up 35.3% on 2H22 and 26.4% on 1H22. Revenue growth was driven by an increase in the volume of consultations delivered to patients together with a contractual inflationary increase in our price per consultation.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Gross profit in 1H23 was £8.3 million, up 38.8% on 2H22 and 31.7% on 1H22. Gross margins continued to improve from 41.8% in 1H22, to 42.5% in 2H22 and up to 43.6% in 1H23. The increase from 2H22 to 1H23 is primarily driven by the increased price received from AXA Health, with a small benefit seen from the launch of MCW in mid-June 23.

Contribution in 1H23 was £4.7 million, up 66.8% on 2H22 and 50.8% on 1H22. Contribution margin of 24.6% was 4.0ppt higher than 1H22 and 4.6ppt higher than 2H22. The 2H22 improvement was driven by a 6% reduction in the average operating cost per consultation resulting from a range of efficiency gains.

EBITDA loss in 1H23 was £3.5 million, a decrease of 37.2% on 2H22 and 66.8% on 1H22. This is driven by the above improvements to gross profit and contribution, together with reductions in non-operating costs. The table below shows the underlying movement in non-operating costs, after excluding one off items:

£m's	1H23	1H22	Change	%	2H22	Change	%
Sales and marketing costs	0.4	1.3	(0.9)	*(69.1%)*	0.5	(0.1)	*(17.6%)*
Technology costs	1.5	4.3	(2.8)	*(65.0%)*	3.1	(1.6)	*(52.0%)*
General and administration costs	6.7	8.4	(1.8)	*(21.2%)*	6.3	0.4	*6.1%*
Other operating income	(0.3)	(0.3)	-	-	(0.3)	-	-
Share based payments	0.0	0.2	(0.2)	*(95.0%)*	(1.4)	1.4	*100.7%*
Total non-operating costs	**8.3**	**13.9**	**(5.7)**	***(40.6%)***	**8.2**	**0.1**	***1.1%***
Less share based payments	(0.0)	(0.2)			1.4		
Less restructuring costs	-	(1.6)			-		
Underlying non-operating costs	**8.3**	**12.1**	**(3.9)**	***(31.9%)***	**9.6**	**(1.3)**	***(13.8%)***

Adjusting for exceptional costs, underlying non-operating costs were £8.3m, a 13.8% reduction on 2H22 and 31.9% reduction on 1H22. The reduction from 1H22 to 1H23 was driven primarily by the one-off restructuring exercise in 1H22 which reduced ongoing salary costs across all departments. The reduction from 2H22 to 1H23 is primarily driven by the £1.6m reduction in technology costs. £1.1m of this reduction was driven by an increase in the quantity of costs capitalised in the period (£1.6m in 1H23 vs. £0.5m in 2H22), with the balance of £0.5m being a reduction in overall spend in the department driven by efficiency gains.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Operating Cash flow

Operating cash flow trend largely followed EBITDA trend in the period when adjusted for non-cash items:

£m's	1H23	1H22	Change	%	2H22	Change	%
EBITDA	**(3.5)**	**(10.7)**	**7.1**	***66.8%***	**(5.6)**	**2.1**	***1.1%***
Add back share based payments	0.0	0.2			(1.4)		
Add back restructuring costs	-	1.6			-		
Underlying EBITDA	**(3.5)**	**(8.9)**	**5.3**	***60.2%***	**(7.0)**	**3.5**	***49.8%***
Net Operating Cash Flows	**(4.5)**	**(9.1)**	**4.5**	***50.1%***	**(6.0)**	**1.5**	***24.4%***
Add back GP2U cash flows	0.1	0.5			0.2		
Add back restructuring costs	-	1.5			0.1		
Underlying net operating cash flows	**(4.4)**	**(7.1)**	**2.7**	***37.7%***	**(5.7)**	**1.3**	***22.9%***

Net operating cash outflows in 1H23 were £4.5 million, a 24.4% reduction on 2H22 and a 50.1% reduction on 1H22. The reduction in operating cash outflows in 1H22 included £1.5 million of payments in respect of restructuring costs and GP2U related costs. Excluding the impact of these items, operating cash outflows in 1H23 decreased 22.9% on 2H22 and 37.7% on 1H22.

The reduction against both periods was mostly driven by the same factors driving the improvements in EBITDA. The variances between EBITDA and net operating cash flows are primarily driven by working capital movements related to timing of invoice payments and revenue receipts, which are often lumpy in nature and do not correspond exactly with revenue and cost in the related period.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Unaudited Interim Condensed Financial Statements

Prepared under International Accounting Standard 34 for the six month period ended 30 June 2023

Interim Condensed Statement of Comprehensive Income

For the six months ended 30 June 2023

	Note	**30 June 2023 Unaudited £'000**	*30 June 2022 Unaudited £'000*
Revenue	3	**19,154**	*15,154*
Cost of sales		**(10,810)**	*(8,817)*
Gross profit		**8,344**	*6,337*
Administrative expenses	6	**(13,321)**	*(18,259)*
Other operating income	7	**307**	*321*
Operating loss	8	**(4,670)**	*(11,601)*
Share of profit/(loss) of joint venture	14	**27**	*158*
Finance income		**7**	*1*
Finance costs	9	**(202)**	*(14)*
Loss before taxation		**(4,838)**	*(11,456)*
Tax credit	10	**560**	*113*
Loss for the financial period from continuing operations		**(4,278)**	*(11,343)*
Loss on discontinued operations, net of tax	5	**(1,872)**	*(267)*
Total comprehensive loss for the period		**(6,150)**	*(11,610)*
Loss per share		**£**	£
Basic and diluted EPS	11	**(0.02)**	(0.03)
Basic and diluted EPS – continuing operations	11	**(0.01)**	(0.03)

The notes on pages 16 to 29 form part of these interim condensed consolidated financial statements.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Interim Condensed Consolidated Statement of Financial Position

	Note	30 June 2023 Unaudited £'000	31 December 2022 Audited £'000
Non-current assets			
Property, plant and equipment	12	**1,012**	*1,220*
Intangible assets	13	**6,497**	*9,131*
Interest in joint venture	14	**1,993**	*1,966*
Total non-current assets		**9,502**	*12,317*
Current assets			
Trade and other receivables: due within one year	15	**4,771**	*3,893*
Corporation tax receivable		**755**	*392*
Cash at bank and in hand		**6,194**	*5,406*
Assets in disposal groups classified as held for sale	5	**1,760**	-
Total current assets		**13,480**	*9,691*
Current liabilities			
Trade and other payables: due within one year	16	**(7,609)**	*(8,136)*
Loans and borrowings	18	**(2,308)**	-
Liabilities in disposal groups classified as held for sale	5	**(377)**	-
Total current liabilities		**(10,294)**	*(8,136)*
Non-current liabilities			
Trade and other payables: due after one year	17	**(1,169)**	*(1,375)*
Loans and borrowings	18	**(5,343)**	-
Deferred tax liabilities		**-**	*(209)*
Total non-current liabilities		**(6,512)**	*(1,584)*
Net assets		**6,176**	*12,288*
Capital and reserves			
Called up share capital		**78**	*78*
Share premium account		**56,212**	*56,212*
Other reserves		**2,116**	*2,078*
Profit and loss account		**(52,230)**	*(46,080)*
Total equity		**6,176**	*12,288*

The notes on pages 16 to 29 form part of these interim condensed consolidated financial statements. The interim condensed financial statements were approved and authorised for issue by the Board and were signed on its behalf by:

DocuSigned by:
John Stier
8F477F2353CF4DD...

John Stier, Chairman 30 August 2023

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2023

	Called up share capital Unaudited £'000	Share premium account Unaudited £'000	Other reserves Unaudited £'000	Profit and Loss Account Unaudited £'000	Total equity Unaudited £'000
At 1 January 2023	**78**	**56,212**	**2,078**	**(46,080)**	**12,288**
Comprehensive loss for the period	-	-	-	(6,150)	**(6,150)**
Total comprehensive loss for the period	-	-	-	(6,150)	**(6,150)**
Share based payments	-	**-**	16	-	**16**
Foreign exchange movements	-	**-**	22	-	**22**
At 30 June 2023	**78**	**56,212**	**2,116**	**(52,230)**	**6,176**

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2022

	Called up share capital Unaudited £'000	Share premium account Unaudited £'000	Other reserves Unaudited £'000	Profit and Loss Account Unaudited £'000	Total equity Unaudited £'000
At 1 January 2022	**72**	**50,418**	**3,287**	**(24,047)**	**29,460**
Comprehensive loss for the period	-	-	-	(11,610)	**(11,610)**
Total comprehensive loss for the period	-	-	-	(11,610)	**(11,610)**
Shares issued during the period*	6	6,064	-	-	6,070
Share based payments	-	**-**	185	-	**186**
Foreign exchange movements			(22)		
At 30 June 2022	**78**	**56,212**	**3,451**	**(35,657)**	**24,084**

*Shares issued during the period relate to a capital raising and security purchase plan exercise completed in March 2022.

The notes on pages 16 to 29 form part of these interim condensed consolidated financial statements.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Interim Condensed Consolidated Statement of Cash Flows

	Period ended 30 June 2023 Unaudited £'000	*Period ended 30 June 2022 Unaudited £'000*
Cash flows from Operating Activities		
Receipts from customers	**18,356**	*16,568*
Payments to suppliers and employees	**(23,082)**	*(25,905)*
Finance income received	**7**	*1*
Finance cost paid	**(1)**	*(1)*
Government grants and tax incentives	**196**	*267*
Total Cash flows from Operating Activities	**(4,524)**	*(9,070)*
Cash flows from Investing Activities		
Payment for property, plant and equipment	**(128)**	*(78)*
Purchase of intangible fixed assets	**(1,570)**	*(1,515)*
Total Cash flows from Investing Activities	**(1,698)**	*(1,593)*
Cash flows from Financing Activities		
Payments to suppliers in relation to equity issue	**-**	*(339)*
Proceeds from equity issue	**-**	*6,409*
Proceeds from debt	**7,500**	*-*
Repayment of loans	**(415)**	*(92)*
Total Cash flows from Financing Activities	**7,085**	*5,978*
Net Cash flows	**863**	*(4,685)*
Cash and cash equivalents at beginning of period	**5,406**	*17,068*
Effect of movement in exchange rates on cash held	**(27)**	*17*
Cash and cash equivalents at the end of period	**6,242**	*12,400*
Included in cash and cash equivalents per the balance sheet	6,194	12,400
Included in the assets of the disposal group	48	-

The notes on pages 16 to 29 form part of these interim condensed consolidated financial statements.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Notes to the Interim Condensed Financial Statements

For the six month period ended 30 June 2023

1. Corporate information

Doctor Care Anywhere Group PLC ('the Company') and its subsidiary undertakings (together referred to as the 'Group') are engaged in digital healthcare service and development.

Doctor Care Anywhere Group PLC is a public company limited by shares and registered in England and Wales, registered number 08915336. Its registered office is located at 13-15 Bouverie Street, 2nd Floor, London, England, EC4Y 8DP. It is listed on the Australian Securities Exchange (ASX:DOC).

2. Significant accounting policies

2.1. Basis of preparation

The unaudited interim condensed consolidated financial statements cover Doctor Care Anywhere Group PLC and the entities it controlled at the end of, or during, the half year ended 30 June 2023 (referred to as the 'Group'), and have been prepared in accordance with IAS 34, Interim Financial Reporting. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements prepared in accordance with UK-adopted international accounting standards.

2.2. Going concern

These financial statements have been prepared on a going concern basis, which assumes that the Group will continue to be able to meet its liabilities as they fall due for the foreseeable future, which is defined as a period of not less than twelve months from the signing of these accounts.

The Company has prepared a cash flow forecast through to August 2024 on a going concern basis, and the directors have considered this forecast and a range of sensitivities carefully. Provided that the Group achieves its forecast it will continue to be able to meet its liabilities as they fall due. For this reason, the Company continues to adopt the going concern basis of accounting in preparing these consolidated financial statements.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

2.3. Estimates and Judgements

The preparation of the interim financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. These estimates, judgements and assumptions are based on historical experience and other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates. The critical accounting judgements and the major sources of estimation uncertainty were the same as those described in the previous annual financial statements for the year ended 31 December 2022. Details of the estimates and judgements are included on page 68 of the 2022 Annual Report.

3. Revenue

	Period ended 30 June 2023 Unaudited £'000	*Period ended 30 June 2022 Unaudited £'000*
Utilisation	**17,870**	*14,258*
Subscription	**1,281**	*1,129*
Other	**3**	*3*
Total revenue	**19,154**	*15,390*

Revenue streams are analysed between Utilisation, Subscription and Other services as follows:

Utilisation revenue

UK & Republic of Ireland: Individually purchased consultations: revenue is recognised at a point in time, when the one distinct performance obligation, the consultation, is complete.

Australia: Revenue is recognised at a point in time, when the one distinct performance obligation, the consultation, is complete. This revenue is recognised net of clinician costs.

Subscription revenue

Monthly or Annual service subscription: there is one distinct performance obligation, being the provision of virtual healthcare services. Revenue from virtual healthcare services is recognised in the accounting period in which the services are rendered. The contracts are satisfied monthly over the contract term. Revenue is recognised over time, on a systematic basis over the period of the contract, as this represents the pattern of delivery of the performance obligation to customers.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Other revenue

- **Minimum number of purchased consultations**: some customers purchase consultations as a bundle for a fixed amount which entitles them to a minimum number of consultations per period. At the end of the period and if the actual number of consultations is less than the minimum number in the bundle, the revenue in respect of the unutilised days is recognised in full.

- **Technology platform licensing**: revenue is deferred and recognised evenly over time, over the period for which the licence is granted.

A **contract asset** is recognised for revenue where the performance obligation (being the provision of utilisation and subscription services) has been completed, but payment remains conditional on acceptance by the customer. Once invoiced, the amount recognised as contract assets is reclassified to trade receivables.

A **contract liability** is recognised if a payment is received or a payment is due (whichever is earlier) from a customer before the Group transfers the related goods or services or for instances where the customer is invoiced in advance. Contract liabilities are recognised as revenue when the Group performs under the contract (i.e., transfers control of the related goods or services to the customer). Contract liabilities arise from annual service subscriptions and technology platform licensing.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

4. Segmental reporting

The Group provides virtual healthcare services and technology platform licensing. within the United Kingdom and the Republic of Ireland. Historically it also provided services in Australia that ceased on the sale of GP2U in July 2023. The following table represents this Geographic split for the period ended 30 June 2023:

Period ended 30 June 2023	UK and Republic of Ireland	Australia	**Total**
	£'000	£'000	**£'000**
Revenue	19,154	-	**19,154**
Cost of sales	(10,810)	-	**(10,810)**
Administrative expenses	(13,321)	-	**(13,321)**
Other operating income	307	-	**307**
Share of profit of joint venture	27	-	**27**
Finance income	7	-	**7**
Finance expense	(202)	-	**(202)**
Tax	560	-	**560**
Loss on discontinued operations	-	(1,8,72)	**(1,872)**
Loss for the financial year	**(4,278)**	**(1,872)**	**(6,150)**
Assets on continued operations	21,222	-	**21,222**
Assets on discontinued operations	-	1,760	**1,760**
Liabilities on continued operations	(16,429)	-	**(16,429)**
Liabilities on discontinued operations	-	(377)	**(377)**
Net assets/(liabilities)	**4,793**	**1,383**	**6,176**

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

5. Discontinued Operations

On 4 June 2023, the Company announced the sale of its Australian subsidiary GP2U for A$3.0m to My Emergency Doctor. The consideration comprised of $2.5m unlisted ordinary shares in MED and $0.5m cash adjusted for normal working capital. The sale was completed on 9 July 2023, and consequently GP2U's operations have been classified as discontinued for the period ended 30 June 2023.

The result from discontinued operations in the period was determined as follows:

	Period ended 30 June 2023 Unaudited £'000	*Period ended 30 June 2022 Unaudited £'000*
Revenue	**352**	*236*
Administrative expenses	**(519)**	*(515)*
Other operating income	**-**	*12*
Tax	**28**	-
Intangible asset impairment	**(1,733)**	-
Loss after tax	**(1,872)**	*(267)*

Intangible asset impairment relates to an impairment of GP2U intangible assets down to the fair value less costs to sell.

The net assets classified as held for sale are broken down as follows:

	As at 30 June 2023 Unaudited £'000
Assets	
Fixed assets	**5**
Intangible assets	**1,576**
Trade receivables	**92**
Prepayments	**11**
Contract assets	**28**
Cash	**48**
	1,760
Liabilities	
Trade payables	**6**
Other taxation and social security	**106**
Accruals	**40**
Contract liabilities	**8**
Other payables	**36**
Deferred tax	**181**
	377

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

6. Administrative expenses

	Period ended 30 June 2023 Unaudited £'000	*Period ended 30 June 2022 Unaudited £'000*
Operating costs	**3,636**	*3,215*
Technology costs	**1,489**	*4,255*
Sales and Marketing costs	**412**	*1,332*
General and Administration costs	**7,784**	*9,457*
	13,321	*18,259*

Operating costs include a variety of expenses attributable to running the Group, including a number of support functions.

Technology costs include the expenses attributable to the development and maintenance of the Group's intellectual property which do not meet the capitalisation criteria under IAS 38.

Sales and Marketing costs include the expenses attributable to the selling and marketing of the Group's services.

General and Administration costs include the expenses attributable to supporting the Group's operating functions, depreciation, amortisation, and share-based payments.

7. Other Operating Income

Other operating income reported in the Interim Condensed Consolidated Statement of Comprehensive Income consists of the following:

	Period ended 30 June 2023 Unaudited £'000	*Period ended 30 June 2022 Unaudited £'000*
Recharges to joint venture	**305**	*305*
Foreign exchange gains	**2**	*28*
	307	*333*

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

8. Operating loss

The operating loss is stated after charging/(crediting):

	Period ended 30 June 2023 Unaudited £'000	Period ended 30 June 2022 *Unaudited* *£'000*
Cost of sales employee costs	**5,897**	*5,778*
Cost of sales contractor costs	**4,901**	*3,038*
Administrative expenses employee costs	**7,524**	*11,337*
Administrative expenses contractor costs	**1,806**	*3,033*
Depreciation	**300**	*242*
Amortisation of intangible assets	**806**	*656*
Exchange difference	**(2)**	*(28)*

Employee costs consist of:

	Period ended 30 June 2023 Unaudited £'000	Period ended 30 June 2022 *Unaudited* *£'000*
Wages and salaries	**11,986**	*14,929*
Social security costs	**1,251**	*1,787*
Costs of defined contribution scheme	**168**	*213*
Share-based payment	**16**	*186*
	13,421	*17,115*

9. Finance costs

Finance costs consist of the following:

	Period ended 30 June 2023 Unaudited £'000	*Period ended 30 June 2022 Unaudited* *£'000*
IFRS 16 lease liability charge	**50**	*13*
Loan interest	**152**	*1*
	202	*14*

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

10. Income tax

The Income tax below relates to the Research and Development tax claim that the group submits annually. No deferred tax asset has been recognised on the Group's losses.

	Period ended 30 June 2023 Unaudited £'000	*Period ended 30 June 2022 Unaudited £'000*
Current income tax credit	**560**	*113*

11. Earnings per share

Basic EPS is calculated by dividing the total comprehensive loss for the period attributable to equity holders of the parent by the weighted average number of equity shares outstanding during the period.

Diluted EPS is calculated by dividing the total comprehensive loss for the period attributable to equity holders of the parent (after adjusting for potential inflows/outflows on all dilutive potential shares) by the weighted average number of equity shares outstanding during the period plus the weighted average number of equity shares that would be issued on conversion of all the dilutive potential equity shares into equity shares.

There is no difference in the total comprehensive loss for the period or the weighted average number of equity shares used for the calculation of basic and diluted loss per share, as the effect of all potentially dilutive shares outstanding was anti-dilutive.

	Period ended 30 June 2023 Unaudited £'000	*Period ended 30 June 2022 Unaudited £'000*
Total comprehensive loss for the period	**6,150**	11,610
Total comprehensive loss for the period – continuing operations	**4,250**	11,610
Weighted number of equity shares:		
Ordinary shares	**366,672,247**	354,334,356
Weighted number of equity shares: for calculation of Basic and Diluted EPS	**366,672,247**	354,334,356
Loss per share	**£**	*£*
Basic and diluted	**(0.02)**	(0.03)
Basic and diluted – continuing operations	**(0.01)**	(0.03)

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

12. Property, plant and equipment

During the six months ended 30 June 2023, the Group acquired computer equipment and office furniture with a cost of £34,675 (30 June 2022: £102,794).

13. Intangible assets

During the six months ended 30 June 2023, the Group capitalised software development costs of £1,569,397 (30 June 2022: £1,515,338). Software development costs of £3,823 relating to third party software installation were incurred by the Group during the six months ended 30 June 2023 (30 June 2022: £6,378).

During the six months ended 30 June 2023, intangible assets with a carrying value of £1,575,548 relating to GP2U were moved from non-current intangible assets to current assets due to their classification as an asset held for sale (see note 5). Prior to the disposal, an impairment of £1,733,000 was recognised in relation to these assets, being the difference between the carrying value of those assets at 30 June 2023 and the fair value less cost to sell of the asset.

14. Interest in joint venture

Movement in the Group's investment in joint venture during the financial period was as follows:

	Unaudited £'000
Balance as at 30 June 2022	**2,270**
Share of loss of joint venture from 1 July to 31 December 2022	(304)
Balance as at 31 December 2022	**1,966**
Share of profit of joint venture from 1 January to 30 June 2023	27
Balance as at 30 June 2023	**1,993**

15. Trade and other receivables

The following balances are due to be realised within one year of the reporting date:

	As at 30 June 2023 Unaudited £'000	As at 31 December 2022 Audited £'000
Trade receivables	**3,562**	1,558
Other receivables	**63**	504
Prepayments	**1,129**	1,457
Contract assets	**17**	374
	4,771	3,893

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

16. Trade and other payables: Amounts falling due within one year

	As at 30 June 2023 Unaudited £'000	As at 31 December 2022 Audited £'000
IFRS 16 lease liability <1 year	**369**	349
Trade payables	**904**	2,344
Other taxation and social security	**800**	811
Other payables	**-**	57
Accruals	**4,548**	4,237
Contract liabilities	**988**	338
	7,609	8,136

17. Trade and other payables: Amounts falling due after one year

	As at 30 June 2023 Unaudited £'000	As at 31 December 2022 Audited £'000
IFRS 16 lease liability >1 year	**419**	620
Other payables	**-**	5
Contract liabilities	**750**	750
	1,169	1,375

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

18. Loans and borrowings

As at 30 June 2023 the Group had the following loans and borrowings:

	As at 30 June 2023 Unaudited £'000	*As at 31 December 2022 Audited £'000*
Current liabilities		
Amounts falling due within one year	**2,308**	-
Non-current liabilities		
Amounts falling due after one year	**5,343**	-

Both the current and non-current amounts relate to a loan facility secured with AXA PPP Healthcare Group Limited. The key terms of this loan are as follows:

- Maturity date of 30 November 2026
- Interest charged at 5% per annum, accruing quarterly and paid in full on maturity date
- Principal amount repaid in 13 quarterly instalments from 30 November 2023
- Loan facility of £10.0m with £7.5m drawn down as at 30 June 2023
- DCA required to maintain look forward 12 month minimum cash balance of £3.0m throughout loan period.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

19. Financial instruments

As at 30 June 2023 the Group has the following financial assets and financial liabilities:

	As at 30 June 2023 Unaudited £'000	*As at 31 December 2022 Audited £'000*
Financial assets		
Current assets		
Held at amortised cost:		
Cash and cash equivalents	**6,194**	*5,406*
Other financial assets	**3,625**	*2,453*
Total assets held at amortised cost	**9,819**	*7,859*
Financial liabilities		
Current liabilities		
Held at amortised cost:		
Loans and borrowings	**2,308**	-
Other financial liabilities	**5,821**	*6,987*
	8,129	*6,987*
Non-current liabilities		
Held at amortised cost:		
Loans and borrowings	**5,343**	-
Other financial liabilities	**419**	*1,374*
	5,762	*1,374*

Prepayments, contract assets and liabilities under the scope of IFRS 15, and tax and social security balances, are not considered financial instruments and are excluded from the table above.

Other current financial assets comprises trade and other debtors (see note 15). Current financial liabilities comprise IFRS 16 lease liabilities <1 year, trade payables, accruals, other payables (see note 16). Non-current financial liabilities comprise IFRS 16 lease liabilities >1 year and other payables (see note 17).

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

20. Share options

The Group grants share options to certain of the Company's employees. The options have a range of vesting periods and exercise conditions.

The share-based payment charge included in the profit and loss account for the six months ended 30 June 2023 was £16,470 (30 June 2022: £185,776).

	Weighted average exercise price (£)	**Number**	Weighted average exercise price (£)	Number
	Period ended 30 June 2023 Unaudited	**Period ended 30 June 2023 Unaudited**	Period ended 30 June 2022 Unaudited	Period ended 30 June 2022 Unaudited
Outstanding at beginning of the period	**0.31**	**10,090,423**	0.36	28,981,320
Granted during the period	**-**	**-**	0.29	769,105
Exercised during the period	**-**	**-**	-	-
Lapsed during the period	**0.25**	**31,875**	0.35	3,896,220
Outstanding at the end of the period	**0.30**	**10,058,548**	0.37	25,854,205
Exercisable at the end of the period	**0.22**	**8,243,203**	0.25	9,842,144

The range of exercise prices in respect of options outstanding at 30 June 2023 is £0.05 to £0.59 (30 June 2022: £0.05 to £0.59). The weighted average remaining contractual life of outstanding options at 30 June 2023 is 6.1 years (30 June 2022: 5.9 years).

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

21. Related parties

For the six month period ended 30 June 2023, the Directors considered themselves, the Chief Executive Officer and the Acting Chief Financial Officer as key management personnel. For the six month period ended 30 June 2022, the Directors considered themselves, the Chief Operating Officer, the Chief Financial Officer & Company Secretary and the Chief Medical Officer as key management personnel. Key management personnel remuneration for the periods was as follows:

	Period ended 30 June 2023 Unaudited £'000	*Period ended 30 June 2022 Unaudited £'000*
Short-term employee benefits	**336**	*506*
Company contributions to defined contribution pension schemes	**1**	*1*
Share-based payment charge	**1**	*117*
	338	*624*

Amounts owed to the Group by Key Management Personnel at 30 June 2023 was £Nil (31 December 2022: £12,708). Loans of £6,250 were made to each of Jonathan Baines and Bayju Thakar in advance of the ASX listing in December 2020 to enable them to incorporate DCA SaleCo PLC, which was required to facilitate the listing. These loans were repaid in 2022.

During the six months to 30 June 2023 the company made sales of £Nil (for the six month period to 30 June 2022: £4,685) to Talbot Baines Limited, a company with a common director.

All transactions with related parties were conducted on an arm's length basis under normal market terms and conditions.

22. Events after the reporting period

In July 2023, the Group drew down the third and final tranche of the AXA loan of £2.5m following meeting of conditions precedent.

On 9 July 2023, the Group completed the sale of GP2U to My Emergency Doctor (MED) for A$3.0m, comprising $2.5m of unlisted ordinary shares in MED and $0.5m in cash adjusted for normal working capital.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Directors' Declaration

In the directors' opinion:

a. The financial statements and notes set out on pages 11 to 29 are in accordance with the Corporations Act 2001, including:

i) Complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements; and

ii) Giving a true and fair view of the consolidated entity's financial position as at 30 June 2023 and of its performance for the half-year ended on that date; and

b. There are reasonable grounds to believe that Doctor Care Anywhere Group PLC will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.

DocuSigned by:
John Stier
3F477F2353CF4DD...

John Stier

Chairman
Doctor Care Anywhere Group PLC

Date: 30 August 2023

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Independent Review Report to Doctor Care Anywhere Group PLC

Conclusion

We have reviewed the condensed set of financial statements in the half-yearly financial report of Doctor Care Anywhere Group PLC (the 'company') for the six months ended 30 June 2023 which comprises the Interim Condensed Statement for Comprehensive Income, the Interim Condensed Consolidated Statement of Financial Position, Interim Condensed Consolidated Statement of Changes in Equity, Interim Condensed Consolidated Statement of Changes in Equity, the Interim Condensed Consolidated Statement of Cash Flows and the Notes to the Interim Condensed Financial Statements.

Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2023 is not prepared, in all material respects, in accordance with UK adopted International Accounting Standard 34, 'Interim Financial Reporting'.

Basis for conclusion

We conducted our review in accordance with International Standard on Review Engagements (UK) (ISRE (UK)) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" (ISRE (UK) 2410). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

As disclosed in note 2, the annual financial statements of the Group are prepared in accordance with UK-adopted international accounting standards. The condensed set of financial statements included in this half yearly financial report has been prepared in accordance with UK adopted International Accounting Standard 34, "Interim Financial Reporting".

We have read the other information contained in the half-yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Conclusions related to going concern

Based on our review procedures, which are less extensive than those performed in an audit as described in the Basis of conclusion section of this report, nothing has come to our attention to suggest that management have inappropriately adopted the going concern basis of accounting or that management have identified material uncertainties relating to going concern that are not appropriately disclosed.

This conclusion is based on the review procedures performed in accordance with this ISRE UK, however future events or conditions may cause the entity to cease to continue as a going concern.

In our evaluation of the directors' conclusions, we considered the inherent risks associated with the group's business model including effects arising from macro-economic uncertainties such as the cost of living crisis (including high inflation), we assessed and challenged the reasonableness of estimates made by the directors and the related disclosures and analysed how those risks might affect the group's financial resources or ability to continue operations over the going concern period.

Directors' responsibilities

The half-yearly financial report is the responsibility of, and has been approved by, the directors.

In preparing the half-yearly financial report, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the review of the financial information

Our responsibility is to express a conclusion to the company on the condensed set of financial statements in the half-yearly financial report based on our review.

Our conclusion, including our conclusions relating to going concern, are based on procedures that are less extensive than audit procedures, as described in the Basis for conclusion paragraph of this report.

Use of our report

This report is made solely to the company, as a body, in accordance with ISRE (UK) 2410. Our review work has been undertaken so that we might state to the company those matters we are required to state to it in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company as a body, for our review work, for this report, or for the conclusion we have formed.

DocuSigned by:
Grant Thornton UK LLP
6C35E89A0582465...

Grant Thornton UK LLP
Statutory Auditor, Chartered Accountants
London, UK
Date: 30 August 2023

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Shareholder Information

The information set out below was correct as at 27 July 2023.

Distribution of Shareholders

Analysis of numbers of shareholders by size of holding:

Range	Total holders	Shares	% of issued capital
1 - 1,000	2,123	1,400,335	0.38
1,001 - 5,000	2,265	5,982,569	1.63
5,001 - 10,000	688	5,437,031	1.48
10,001 - 100,000	1,081	33,767,388	9.21
100,001 +	202	320,007,311	87.29
Total	**6,359**	**366,594,634**	**100**

Unmarketable Parcels

Analysis of numbers if shareholders by size of holding:

Range	Minimum Parcel Size	Holders	Units
Minimum $500 parcel at $0.570 per unit	8,772	4,833	10,439,140

Twenty Largest Quoted Equity Holders

Rank	Name	Units	% of issued capital
1	UBS Nominees Pty Ltd	71,541,763	19.52
2	Carani Holdings Limited	44,264,604	12.07
3	Vijay Patel	26,094,880	7.12
4	Citicorp Nominees Pty Limited	21,567,214	5.88
5	BGF Nominees Limited <BGF Investments LP A/C>	18,042,248	4.92
6	Buttonwood Nominees Pty Ltd	8,791,505	2.40
7	Bhikhu Patel	8,698,178	2.37
8	Hadston 1 LLP\C	8,587,773	2.34
9	Patagorang Pty Ltd <R W Allen A/C>	8,191,201	2.23
10	HSBC Custody Nominees (Australia) Limited-GSCO ECA	5,551,623	1.51
11	BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client DRP>	4,704,324	1.28
12	BGF Nominees Limited <BGF Ventures LP A/C>	3,742,855	1.02
13	Indigenous Capital Limited	3,116,420	0.85
14	HSBC Custody Nominees (Australia) Limited-GSI EDA	2,962,557	0.81
15	Mr Kenneth Joseph Hall <Hall Park A/C>	2,500,000	0.68
16	Barnett Waddingham Trustees (1996) Limited <Anthony Banks Ltd P/P A/C>	2,406,855	0.66
16	Barnett Waddingham Trustees (1996) Limited <HRMP Directors P/SCH A/C>	2,406,855	0.66

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

16	Barnett Waddingham Trustees (1996) Limited <MJ Rutherford Ltd D/PF A/C>	2,406,855	0.66
19	Christopher Robin Moore	2,369,224	0.65
20	The Hospitals Contribution Fund of Australia Limited	2,245,236	0.61
Total		**250,192,170**	**68.25**

Substantial Shareholders

Rank	Name	Units	% of Issued Capital	Date of Notice
1	Tiga Trading Pty Ltd	72,961,587	19.90	24/01/2023
2	Thorney Technologies Ltd	72,961,587	19.90	23/01/2023
3	Carani Holdings Limited	44,264,604	12.07	07/03/2022
4	Vijay Patel	37,133,058	10.15	07/03/2022
4	Mark Cotterill	37,133,058	10.13	07/03/2022
4	Bhiku Patel	37,133,058	10.13	07/03/2022
4	Amit Patel	37,133,058	10.13	07/03/2022

DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924

Corporate Directory

Directors

Romana Abdin	Independent Non-Executive Director
David Ravech	Non-Executive Director
John Stier	Independent Non-Executive Chairman
Dr Aleksandra Spencer	Independent Non-Executive Director

Company Secretary

Bianca Foster

Principal Registered Office in the UK

13-15 Bouverie Street,
2nd Floor,
London,
EC4Y 8DP

Share Registrar

Computershare Investor Services Pty Ltd,
452 Johnston Street,
Abbotsford, VIC 3067
Tel: +61 3 9415 4000

Auditor

Grant Thornton UK LLP,
30 Finsbury Square,
London,
EC2A 1AG

Stock Exchange Listing

Doctor Care Anywhere Group PLC's shares are listed on the Australian Securities Exchange (Listing Code: DOC)

UK Company Number and ARBN

Company number: 08915336

ARBN: 645 163 873